Hepatitis C virus (HCV) is the major etiologic agent associated with non-A, non-B hepatitis. This study was designed to assess virologic and serologic markers in hemophiliacs exposed to non-heat-treated and/or virus-inactivated plasma derivatives. Serial bleeds from 48 hemophilic patients were analyzed for the presence of HCV viral RNA sequences as detected by polymerase chain reaction (PCR) and antibodies to structural (core) and nonstructural (C-100 and 33C) proteins by specific dot immunoblot assay. All patients exposed to non-heat-treated products, and four of six patients exposed only to virus inactivated products, had evidence of HCV infection. However, over the 5-yr study period, six exposed patients (13%) consistently lacked detectable anti-C-100 and seven (15%) lost this antibody. HCV viremia (PCR positive) was found in 91% of exposed patients, and was significantly more frequent in HIV seropositive hemophiliacs (P less than 0.05). Six patients had high antibody level to HCV and elevated ALT, but appeared to clear viremia. Four hemophiliacs were HCV seropositive but lacked detectable viremia. These data indicate that hemophiliacs remain persistently infected by HCV and that antibody to the core antigen of HCV is a reliable marker of this transfusion transmissible agent. 
Introduction
Since the early 1980s, viral inactivation of plasma derivatives used for the treatment of hemophiliacs has been the object of intensive research. A large number of techniques for inactivation of infectious agents in plasma derivatives ranging from heat treatment at 60-80°C in dry, humidified, or liquid state (1) (2) (3) (4) (5) (6) , to detergents or chemicals (7), have been developed and evaluated in chimpanzees as well as in previously untreated hemophiliacs. Clinical trials showed that most of these methods effectively inactivated HIV but were only partially effective with the agent of non-A, non-B hepatitis. Unequivocal evidence of non-A, non-B hepatitis prevention was obtained only with high temperature (. 750C), pasteurization in liquid phase, or the solvent-detergent (SD)' method (6) (7) (8) . These clinical results were later confirmed serologically with the discovery of hepatitis C virus (HCV), the virus implicated in posttransfusion non-A, non-B hepatitis, and the development of screening assays for antibody to HCV. Several studies indicated that the prevalence of antibody to the HCV nonstructural C-100 antigen ranged from 61 to 89% in patients with hemophilia A receiving non-heat-treated Factor VIII concentrates, and 22 to 56% in patients receiving exclusively virus-inactivated material (9) (10) (11) (12) (13) . Investigators raised questions as to why all potentially exposed patients were not seropositive to HCV, and why, over time, between 1985-88 , approximately 10% of seropositive hemophiliacs lost reactivity with the C-100-based screening ELISA (9, 14) . One hypothesis suggested that some patients may not develop antibody to this HCV nonstructural protein. Alternatively, the use of virus-inactivated products may limit or eliminate HCV antigenic stimulation and patients who no longer produce virus may return to a seronegative state (seroreversion) (14) .
In order to test these hypotheses, serial serum samples collected 1985-89 from a group of48 hemophiliacs were tested to assess the presence of circulating HCV by polymerase chain reaction (PCR) and the immune response to structural and nonstructural antigens of HCV by dot immunoblot. Results indicate that most HCV-infected hemophiliacs remain chronically infected while receiving virus-inactivated plasma derivatives and that antibody to the core antigen of HCV was a very reliable marker of past and present HCV infection.
Methods
Patients. A group of48 persons with hemophilia A (40) or B (8) (5) . Since 1988, all patients were treated exclusively with a high purity SD-treated Factor VIII (Bio-Transfusion, Les Ulis, France). Patients with hemophilia B received Factor IX concentrate (PPSB, CNTS) non-heat-treated, heat-treated, and SD as for patients with hemophilia A. There were six patients (five with severe and one with moderate hemophilia) who received exclusively a combination of heat-treated and SD-treated products. These six patients and nine others were HIV seronegative, whereas 33 patients were HIV seropositive in 1985 and remained positive. 12 patients age 15 or younger had been vaccinated with HEVAC B (Pasteur vaccine) and all had anti-HBs as only marker of hepatitis B. In addition, 2 of the 36 patients who were HBV infected by transfusion were HBsAg positive; 34 had anti-HBs, 25 anti-HBc, and one had none of these HBV markers although he had received whole blood and plasma derivatives for more than 30 yr.
Detection ofHCVgenomic sequences by PCR. The genomic RNA isolation, cDNA synthesis, and PCR analysis were performed as described by Weiner et al. (15) with PCR primers described by Kubo et al. (16) . Briefly, 50 gl of patient serum were incubated in lysis buffer (50 mM Tris pH 8, 1 mM EDTA, 0.1 M NaCl, 0.5% SDS, 100 gg/ml proteinase K) for 1 hat 370C. RNA was purified by phenol/chloroform extractions. The cDNA synthesis was performed accordingto manufacturer's protocols (Bethesda Research Laboratories, Gaithersburg, MD). PCR conditions were: denaturation at 950C for 1 min, annealing at 420C for 2 min, and extension at 720C for 3 min for 35 cycles. After first round amplification, the PCR-amplified sample was reamplified with a second pair ofprimers which were internal to the original primer pair. The nested-PCR conditions were the same as the first round except only 30 cycles were performed. The PCR products were analyzed on a 1.2% agarose gel, blotted to Hybond-N (Amersham Corp., Arlington Heights, IL), and hybridized to a random primed 32P-labeled HCV DNA insert. Samples positive by PCR were considered viremic. Dot blot immunoassay. Antibodies to HCV gene products were assayed with a semiautomated dot blot immunoassay (MATRIX; Abbott Laboratories, North Chicago, IL) which employs an array ofpurified recombinant antigens spotted on nitrocellulose. This technology has been described in detail (17, 18) . The test panels consisted of the C-100 antigen, which was purchased from Chiron Corporation (Emeryville, CA), plus polypeptides corresponding to putative HCV NS-3 (33C), and 5'-structural sequences encoding for the putative core ofHCV (core) which were expressed in Escherichia coli as fusions with cytosine monophosphate keto deoxy octulosonate (CMP-KDO) synthetase (19) . Each array also contained procedural controls (anti-human IgG and human IgG) to verify sample and reagent addition, as well as a negative control (casein) to adjust for nonspecific binding to the nitrocellulose surface.
The prepared solid phase was incubated in a reaction cell with the test sample (diluted 1:100) for I h at 35°C followed by sequential 30-min incubations at 35°C with biotin-labeled goat anti-human IgG (heavy and light chains), alkaline phosphatase-labeled rabbit antibiotin, and bromochloroindolyl phosphate. Upon completion ofthe incubation with the chromogen, the nitrocellulose surface was dried and reflectance at defined locations within the array was determined to provide an objective measure of the extent ofthe individual reactions.
Reactivity cutoff values were calculated for each antigen based on a 50-member antibody-negative population; sample to cutoff (S/CO or density of reflectance (Dr) ratio) values > 1 were considered positive.
For typical HCV-positive donor specimens, antigen reactivities varied linearly with antibody concentration for S/CO values < 100 (data not shown). Statistical analysis. The two tailed Fischer's exact tests were used to assess statistical differences between comparison groups.
Results
HCV infection. By serological criteria, 46 out of48 multitransfused hemophiliacs (95.8%) had antibody to HCV. Two patients who had received exclusively heat-treated and SD Factor VIII concentrates had no convincing clinical, serologic, or virologic evidence of HCV infection. All 46 HCV seropositive patients had antibodies to at least two ofthe tested antigens. However, among these, six were consistently negative for anti-C-100 and one was consistently negative for anti-33C, but all were positive for antibody to the core protein. Table I and summarized in Table II . Pattern 1 included 10 patients whose samples all tested positive for HCV genome in serum. In addition to apparent, persistent HCV viremia based on PCR data, it is significant that all patients were also seropositive for HIV. Nine patients had either clear (seven) or moderate (two) signs of liver disease and only patient 39 had consistently normal ALT level. HCV antibodies to the three antigens tested were present in all patients on entry. Over time, antibody level to C-100 tended to decline in seven patients and became undetectable in four of them: The mean maximum Dr ratio was 77.5±62.7 (Table II) . Antibody to 33C was initially at high or moderate level, and decreased significantly during the course of the study in five patients. Except for patient 38, antibody to core was at high level in all patients and remained rather stable during the study period.
Pattern 2 included 26 patients (56.5%) whose HCV viremia was intermittently detectable (Table II) . Due to the large number of patients in this group and the absence of particular features, serial sample results are not presented in Table I . Acute (two patients) or chronic liver disease (11 patients) was frequent, while four patients showed no sign ofliver abnormality. HIV seropositivity was found in 18 patients (69%) from this group. Four patients had no detectable antibody response to C-100 (three patients) or 33C (one patient); all responded to the core protein. The mean Dr ratios of antibody to C-100, 33C, and core were similar to group 1 (Table II) . During the study period, antibody to C-100 ratio declined in 13 patients, becoming undetectable in three of them. Antibody to 33C also declined in 13 patients and as did antibody to core in four patients.
Hepatitis C Virus Infection in Hemophiliacs 1673 Pattern 3 included six patients who were initially viremic and subsequently became negative by PCR. As shown in Table   Ib , these patients had chronic (two patients) or minor liver disease (three patients), and one patient had no sign of liver disease. ALT levels were mostly normal or less than twice the upper normal level. Three patients had no detectable antibody to C-100; the other three had either low or declining levels of antibody. In contrast, four had consistently high anti-33C and two had low antibody titers that became undetectable. All patients had consistently high anticore immune response. When compared with patients in pattern 1, the mean maximum of anti-C-100 was significantly lower in patients with pattern 3 (P < 0.05) and the level ofanticore was higher although the difference was not significant.
Pattern 4 included four patients with no evidence of HCV viremia, although two of them (patients 29 and 42, Table Ic) had severe chronic hepatitis. Patient 19 ( Fig. 1) was HIV antibody negative, had no sign of liver disease, and a decreasing level of all three antibodies to HCV. Patient 26 had fluctuating levels ofantibody to 33C and core, and had no detectable anti-C-100 in the final sample. He had a slightly elevated ALT level. and 33 had no evidence of HCV infection and normal ALT levels, and are presented at the end of Table Ic. HCV infection in hemophiliacs receiving virus inactivated plasma derivatives. Four out ofsix patients who received exclusively heat-treated and SD-treated products (Table III) had evidence of HCV infection. Patients 1, 25, and 30 were 6-8 yr old and had severe hemophilia A. In 1985, they already had antibody to the three HCV antigens tested and viremia was found in two to three samples of each patient over the study period. The fourth patient (number 16, Fig. 2 ), a 22-yr-old with mild hemophilia A, as well as patient 24 (data not shown) who had received both heat-treated and non-heat-treated products, were HCV seronegative in 1985 but seroconverted to HCV. The immune response to C-100 was apparently lower than to 33C or core. Over time, the antibody level to C-100 declined rapidly but levels of anti-33C and core remained high. HCV viremia was detected one (patient 16) and two years (patient 24) after seroconversion, respectively. Interestingly, patient 24 maintained normal ALT levels during the entire study period. Data compatible with HCV superinfection during the course of the study were found in three additional cases. Patients 44 (Fig. 3) , 41, and 48 (data not shown) had a very low level of antibody to C-100 (range 2-3 Dr ratio) and high levels of antibody to 33C and core in 1985. Levels of antibody to C-100 subsequently increased to a mean reflectance ratio of 82.2±40.1 (range 28-141) and then decreased over 2-3 yr to a mean level of 36±29.7 (range 0-77). In two of the three cases (patients 41 and 44), HCV RNA was not detectable initially but viremia became evident in these patients simultaneously or within 2 yr of the increased C-100 level. All patients had a concomitant elevation of ALT level. Patient 41 was a chronic carrier of hepatitis B surface antigen and had a previously reported delta hepatitis (20) -50 Figure 3 . HCV markers suggestive of superinfection in a hemophiliac. ALT levels, HCV virologic and serologic markers ofpatient 44 who had chronic hepatitis before 1984. While antibody to HCV 33C and core remained at a high level, an immune response to C-100 was observed concomitant with a peak of ALT and transitory HCV viremia.
was under a prophylactic regimen of 20 U/kg of heat-treated intermediate purity Factor VIII every other day in 1986-87 (Fig. 3) . He had developed immunity against HBV. Patient 48 had hemophilia B, received non-heat-treated and subsequently heat-treated PPSB during the period of his response to C-100 (30 U/kg per mo). He had serologic evidence of immunity to HBV.
Role ofHIVin HCV infection. The various results collected in this study were analyzed according to the HIV immune status of patients. Among 46 HCV infected hemophiliacs, 33 (72%) were HIV seropositive and 13 seronegative. The mean levels of antibody to C-100, 33C or core, and the variations in levels of antibody to C-100 (undetectable, declining, or consistently high over time), were similar between the two groups. In contrast, the percentage ofviremic samples in HIV seropositive patients (105/161 or 65.2%) was significantly higher than in seronegative patients (21/60 or 35%, P < 0.01). A majority of HIV seropositive patients had chronic liver disease. 20 of the 33 seropositive patients (67%) were classified as code 1 (See Table I ), compared to 5 of the 13 patients (38%) in the HIV seronegative group. However, the mean levels of ALT were similar between the two groups (63.6±51.0 in HIV seropositive vs. 49.0±60.6 in HIV seronegative patients).
Discussion
The data collected in this study differ from previously reported results on HCV in hemophilia. All exposed patients had serological evidence of HCV infection with the presence of antibody to the core protein of HCV and, in most cases, to the nonstructural 33C antigen. These two proteins were apparently more immunogenic than C-100 since antibody levels were higher and persisted longer. Thus, our data demonstrate that current seronegativity in 20% of the patients was related to a decline of antibody to C-100. However, this apparent seroreversion took place despite continued infection as shown in some patients with patterns 1 or 3 (Table I ). In other anti-C-100 negative patients (15%), the lack of detection by current screening assays (C-100 based) may be attributed in part to the absence of a significant immune response to C-100. These results are consistent with previous observations in similar populations (10, 14, 21) . In contrast, seroreversion for antibody to 33C was infrequent (6.5%) and not observed with anticore.
There was no evidence that HIV infection played a significant role in this mechanism since it was observed with similar frequency irrespective of HIV status.
One of the features of this study was the frequency of viremia found in over 90% of patients over a 5-yr period during which they received successively heat-treated and SD-treated products. In a limited number ofcases, the viremia patterns we described had been identified previously by Garson et (Table Ic) .
The liver condition is probably not related to HBV since HBsAg is not detected and antibodies to surface and core antigens are present. In addition, patients 26 and 42 are HIV infected. Four main hypotheses can be proposed to explain these findings. One is a false negativity of the HCV PCR due to inadequate precautions during sample handling or storage, or, alternatively, significant sequence heterogeneity at the primer or probe levels. Such hypothesis could be confirmed by using a primer pair from a more conserved region ofthe HCV genome such as the 5' noncoding region (26) . A recent report has emphasized the relative diversity of nucleotide sequences in the NS3/NS4 regions that we used in our detection system (14) . The second hypothesis is a variant of HBV or, as previously described, a level of HBV production below the HBsAg detection level (27) . However, the presence of both anticore and antisurface antibody to HBV does not support this explanation. The third hypothesis is that the virus may be replicating in the liver but not released in the blood stream. Finally, a still unidentified hepatotropic virus may be involved. This hypothesis is unlikely since similar concentrates have been used for this and other groups of patients.
This study indicates that in hemophilia all exposed subjects have serological markers of HCV and suggest that HCV is a persistent infection. This feature may not be the rule in other groups of HCV infected patients since the interaction of HIV, HCV superinfection and potentially HBV might interfere with the natural history of HCV infection. The role of HBV, however, is likely to be minimal since eight ofnine HBV vaccinated hemophiliacs had persistent HCV viremia. Prospective studies of patients receiving noninfectious blood products and examination ofliver biopsies for the presence ofviral RNA in hepatocytes should provide a final answer. The fact that, irrespective of HIV, hemophiliacs can be persistently infected and possibly superinfected with HCV suggest a limited efficacy of their immune system against HCV.
